Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer

Lung Cancer

Volumn 61, Issue 1, 2008, Pages 104-108

  Sirera, Rafael ^a   Gil, Mireia ^a   Blasco, Ana ^a   Cabrera, Andrea ^a   Safont, María José ^a   Iranzo, Vega ^a   Cayuela, Diego ^a   Rosell, Rafael ^b   Camps, Carlos ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Biological marker; LOH; Loss of heterozygosity; Non small cell lung cancer; NSCLC; p16 methylation

Indexed keywords

CISPLATIN; GEMCITABINE; PROTEIN P16;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENES, P16; HUMANS; KAPLAN-MEIERS ESTIMATE; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS (GENETICS); RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 45649085773     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.12.005     Document Type: Article

References (22)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 55 (2005) 74-108
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
3. Sanchez-Cespedes M. Dissecting the genetic alterations involved in lung carcinogenesis. Lung Cancer 40 (2003) 111-121
4. Knudson A.G. Chasing the cancer demon. Annu Rev Genet 34 (2000) 1-19
5. Gonzalez-Quevedo R., Iniesta P., Moran A., de Juan C., Sanchez-Pernaute A., Fernandez C., et al. Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer. J Clin Oncol 20 (2002) 254-262
6. Tseng R.C., Chang J.W., Hsien F.J., Chang Y.H., Hsiao C.F., Chen J.T., et al. Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int J Cancer 117 (2005) 241-247
7. Sekido Y., Fong K.M., and Minna J.D. Molecular genetics of lung cancer. Annu Rev Med 54 (2003) 73-87
8. Wiest J.S., Franklin W.A., Otstot J.T., Forbey K., Varella-Garcia M., Rao K., et al. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer Res 57 (1997) 1-6
9. Liggett Jr. W.H., and Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16 (1998) 1197-1206
10. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
11. Bearzatto A., Conte D., Frattini M., Zaffaroni N., Andriani F., Balestra D., et al. p16(INK4A) hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 8 (2002) 3782-3787
12. Benlloch S., Galbis-Caravajal J.M., Martin C., Sanchez-Paya J., Rodriguez-Paniagua J.M., Romero S., et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer 107 (2006) 1859-1865
13. Singhal S., Vachani A., Ntin-Ozerkis D., Kaiser L.R., and Albelda S.M. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11 (2005) 3974-3986
14. Sozzi G., Conte D., Leon M., Ciricione R., Roz L., Ratcliffe C., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21 (2003) 3902-3908
15. Silva J.M., Dominguez G., Garcia J.M., Gonzalez R., Villanueva M.J., Navarro F., et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 59 (1999) 3251-3256
16. Camps C., Sirera R., Bremnes R., Blasco A., Sancho E., Bayo P., et al. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?. Lung Cancer 50 (2005) 339-346
17. Camps C., Sirera R., Bremnes R.M., Rodenas V., Blasco A., Safont M.J., et al. Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer. Anticancer Res 26 (2006) 4905-4909
18. Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., and Minna J.D. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 60 (2000) 4894-4906
19. Sanchez-Cespedes M., Reed A.L., Buta M., Wu L., Westra W.H., Herman J.G., et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 18 (1999) 5843-5849
20. Sekido Y., Fong K.M., and Minna J.D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378 (1998) F21-F59
21. Okami K., Cairns P., Westra W.H., Linn J.F., Ahrendt S.A., Wu L., et al. Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. Int J Cancer 74 (1997) 588-592
22. Sozzi G., Musso K., Ratcliffe C., Goldstraw P., Pierotti M.A., and Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 5 (1999) 2689-2692